Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Gensun Biopharma Inc. has a portfolio in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action. This matter is assigned to 1 distinct examiner and 1 distinct art unit, which centralizes the company's current prosecution activity. This structure indicates that the company's immediate patent strategy is focused on a single technical department and a single individual reviewer.
SCHWECHTER, BRANDON ROSS is the busiest examiner for this portfolio, currently overseeing 1 pending office action. Because the company has only 1 active action, its immediate progress at the patent office is determined by the decisions of this 1 examiner and the standards of their assigned art unit. This focused profile simplifies the management of pending intellectual property. The presence of 1 distinct examiner and 1 distinct art unit suggests a targeted engagement with the patent examination process within the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHWECHTER, BRANDON ROSS | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18562994 | MULTISPECIFIC ANTAGONISTS | SCHWECHTER, BRANDON ROSS | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18562994 | MULTISPECIFIC ANTAGONISTS | SCHWECHTER, BRANDON ROSS | 1674 | §102§103§112 | Non-Final OA | — | Pending | Nov 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGensun Biopharma Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Brandon Ross Schwechter has the most, with 1 of Gensun Biopharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.